<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thyrotropin alfa (recombinant human thyrotropin): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thyrotropin alfa (recombinant human thyrotropin): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Thyrotropin alfa (recombinant human thyrotropin): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12061" href="/d/html/12061.html" rel="external">see "Thyrotropin alfa (recombinant human thyrotropin): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F227397"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Thyrogen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868411"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Thyrogen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F227410"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F227399"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider pretreatment with glucocorticoids for patients in whom local tumor expansion may compromise vital anatomic structures. Oral radioiodine should be administered 24 hours following the second thyrotropin alfa injection (for diagnostic scanning and remnant ablation). Perform diagnostic scanning 48 hours after radioiodine administration (72 hours after the second thyrotropin alfa injection).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b>
<b>IM:</b> 0.9 mg, followed 24 hours later by a second 0.9 mg dose; obtain serum Tg sample 72 hours after the second thyrotropin alfa injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16515bf7-b336-4666-8abd-ca1036d0fc06">Thyroid tissue remnant ablation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid tissue remnant ablation:</b>
<b>IM:</b> 0.9 mg, followed 24 hours later by a second 0.9 mg dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990230"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, elimination is significantly slower in dialysis-dependent end-stage renal disease and TSH level elevation may be prolonged.</p></div>
<div class="block doha drugH1Div" id="F50987540"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F227400"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F227380"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Nausea (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6%), dizziness (2%), fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Altered thyroid hormone levels (increased)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cerebrovascular accident (with and without physiologic symptoms like unilateral weakness), flu-like symptoms (transient; including arthralgia, chills, fever, malaise, myalgia, shivering), hypersensitivity reaction (including dyspnea, flushing, pruritus, skin rash, urticaria), injection site reaction (including bruising, erythema, pain, and pruritus)</p></div>
<div class="block coi drugH1Div" id="F227390"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to thyrotropin alfa or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F227377"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Thyrotropin alfa use may cause a transient (over 7 to 14 days) and significant rise in serum thyroid hormone concentration in patients with substantial<i> in situ</i> thyroid tissue or with functional thyroid cancer metastases. Thyrotropin alfa-induced hyperthyroidism may result in serious complications in patients with certain risk factors (heart disease, advanced age, extensive metastatic disease, or with underlying serious illness); consider hospitalization for administration and subsequent observation. Deaths within 24 hours of thyrotropin alfa administration have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stroke: Postmarketing reports of stroke or symptoms suggestive of stroke (eg, unilateral weakness) have occurred within 3 days (range: 20 minutes to 3 days) of thyrotropin alfa administration in patients without known CNS metastases. The majority of these patients had risk factors for stroke (eg, smokers, history of migraine) or were young females taking oral contraceptives. Patients should be well hydrated prior to thyrotropin alfa administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor growth: Sudden, rapid, and painful growth of residual thyroid tissue or distant metastases may occur following thyrotropin alfa administration. Symptoms are associated with tissue location and include acute hemiplegia, hemiparesis, and vision loss 1 to 3 days after administration. Laryngeal edema, pain at site of distant metastases, and respiratory distress requiring tracheotomy have also been reported. Consider glucocorticoid premedication in patients where local tumor enlargement may compromise vital structures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Patients with known history of heart disease in the presence of significant residual thyroid tissue are at increased risk for thyrotropin alfa-induced hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Thyrotropin alfa elimination is significantly reduced in dialysis-dependent end-stage renal disease, leading to prolonged elevation of TSH levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Elderly patients with residual thyroid tissue are at increased risk for thyrotropin alfa-induced hyperthyroidism.</p></div>
<div class="block foc drugH1Div" id="F227385"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thyrogen: 0.9 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F227373"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323966"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thyrogen Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.9 mg (per each): $2,372.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868412"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thyrogen: 0.9 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F227387"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IM: Administer only by IM injection into the buttock. Do <b>not</b> administer IV.</p></div>
<div class="block use drugH1Div" id="F227386"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b> Adjunctive diagnostic tool for serum thyroglobulin (Tg) testing (with or without radioiodine imaging) in follow-up of patients with well-differentiated thyroid cancer (DTC) who have previously undergone thyroidectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Thyrotropin alfa-stimulated Tg levels are generally lower than and do not correlate with Tg levels after thyroid hormone withdrawal; even when thyrotropin alfa-stimulated Tg testing is performed in combination with radioiodine imaging, there is a risk of missing a thyroid cancer diagnosis or of underestimating disease extent. Anti-Tg antibodies may confound Tg assay and render Tg levels uninterpretable; in such cases, even with a negative or low-stage thyrotropin alfa radioiodine scan, consider further patient evaluation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid tissue remnant ablation: </b> Adjunctive treatment for radioiodine ablation of thyroid tissue remnants after total or near-total thyroidectomy in patients with well-differentiated thyroid cancer without evidence of metastatic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: The effect of thyrotropin alfa on thyroid cancer recurrence &gt;5 years postremnant ablation has not been evaluated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Guideline recommendations:</b> The American Thyroid Association guidelines recommend thyrotropin alfa as a reasonable alternative to thyroid hormone withdrawal prior to remnant ablation or adjuvant therapy in patients with low- or intermediate-risk DTC without extensive lymph node involvement. Thyrotropin alfa may also be considered in intermediate-risk DTC with extensive lymph node disease (but without distance metastases), though the evidence is of lower quality (ATA [Haugen 2016).</p></div>
<div class="block mst drugH1Div" id="F227416"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Thyrogen may be confused with Thyrolar</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300137"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223312"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F54321438"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential when thyrotropin alfa is administered with radioiodine (ATA [Haugen 2016]).</p></div>
<div class="block pri drugH1Div" id="F2738770"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Use of thyrotropin alfa administered with radioiodine is contraindicated during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F17917300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if thyrotropin alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding following diagnostic testing with thyrotropin alfa should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of testing to the mother. Thyrotropin alfa administered with radioiodine is contraindicated in breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F15159242"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for neurologic adverse events (hemiplegia, hemiparesis, stroke, weakness); dyspnea, dysphonia, stridor or other symptoms of local tumor growth, signs/symptoms of hyperthyroidism</p></div>
<div class="block rer drugH1Div" id="F52759491"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">In preparation for radioactive iodine (RAI) remnant ablation or diagnostic testing a goal TSH of &gt;30 milliunits/L is recommended (ATA [Haugen 2016])</p></div>
<div class="block pha drugH1Div" id="F227376"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Thyrotropin alfa, derived from a recombinant DNA source, has the identical amino acid sequence as endogenous human thyroid stimulating hormone (TSH). As a diagnostic tool in conjunction with serum thyroglobulin (Tg) testing, thyrotropin alfa stimulates the secretion of Tg from any remaining thyroid tissues (remnants). Under conditions of successful thyroidectomy and complete ablation, very little serum Tg should be detected under TSH stimulatory conditions; conversely, elevated Tg levels suggest the presence of remnant thyroid tissues. Since the source of TSH is exogenous, stimulation of Tg synthesis can be achieved in euthyroid patients, avoiding the need for thyroid hormone withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">As an adjunctive agent for radioiodine ablation treatment of thyroid cancer tissue remnants, thyrotropin alfa binds to TSH receptors on these tissues, stimulating the uptake and organification of iodine, including radiolabeled iodine (I<sup>131</sup>). Cancerous tissue is destroyed via gamma emission from the radioiodine concentrated in these tissues.</p></div>
<div class="block phk drugH1Div" id="F227389"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 25 ± 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 10 hours (range: 3 to 24 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F227391"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen | Tirotropina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Thyrogyn</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Thyrogen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26462967">
<a name="26462967"></a>Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi:10.1089/thy.2015.0020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/26462967/pubmed" id="26462967" target="_blank">26462967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551128">
<a name="22551128"></a>Mallick U, Harmer C, Yap B, et al, “Ablation With Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer,” <i>N Engl J Med</i>, 2012, 366(18):1674-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/22551128/pubmed" id="22551128" target="_blank">22551128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16384850">
<a name="16384850"></a>Pacini F, Ladenson PW, Schlumberger M, et al, “Radioiodine Ablation of Thyroid Remnants After Preparation With Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study,” <i>J Clin Endocrinol Metab</i>, 2006, 91(3):926-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/16384850/pubmed" id="16384850" target="_blank">16384850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551127">
<a name="22551127"></a>Schlumberger M, Catargi B, Borget I, et a, “Strategies of Radioiodine Ablation In Patients With Low-Risk Thyroid Cancer,” <i>N Engl J Med</i>, 2012, 366(18):1663-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/22551127/pubmed" id="22551127" target="_blank">22551127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thyrogen.1">
<a name="Thyrogen.1"></a>Thyrogen (thyrotropin alfa) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thyrogen.2">
<a name="Thyrogen.2"></a>Thyrogen (thyrotropin alfa) [product monograph]. Toronto, Ontario, Canada: Sanofi Genzyme Canada; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10286 Version 135.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
